May 5, 2026
Restoring Life’s Blueprint
Our Mission & Vision
We envision a world where rare genetic conditions no longer define an individual’s trajectory, ensuring that every child has the opportunity to reach their full potential. Our objective is to accelerate the translation of scientific discovery into meaningful clinical change through AAV therapies that address the underlying genetic causes of rare, life‑limiting diseases.
Gene Therapy for Children Living with Rare Genetic Diseases
Sangrail Biologics partners with advocacy organizations, clinicians, researchers, and regulators to advance transformative therapies for patients affected by rare, devastating diseases. Initially focused on lysosomal storage disorders, we target disease at its genetic source to improve outcomes and quality of life for affected children and their families.
Gene Therapies
Innovation Informed by the Needs of Affected Children and Families
Lysosomal Storage Disorders (LSDs)
Lysosomal storage disorders (LSDs) are a group of rare inherited conditions that affect how cells recycle waste. In children with an LSD, a missing or malfunctioning enzyme allows harmful material such as sugars or fats to build up inside cells. Over time, this buildup damages organs—especially the brain and nervous system—leading to progressive loss of function.
Understanding MPS IIIB (Sanfilippo syndrome Type B)
Mucopolysaccharidosis type IIIB (MPS IIIB) is a particularly devastating LSD. It is caused by a mutation in the NAGLUgene, which provides instructions for making the enzyme α-N-acetylglucosaminidase. Without this enzyme, the body cannot break down a complex sugar called heparan sulfate.
In children with MPS IIIB, heparan sulfate accumulates primarily in the brain. While children often appear healthy at birth, the buildup leads to a “pediatric dementia” characterized by:
- Significant developmental delays and loss of speech.
- Intractable behavioral issues and hyperactivity.
- Progressive cognitive decline and loss of motor function.
- Shortened lifespan, often only into the second decade of life.
AAV: The Breakthrough in Delivery
Adeno-associated virus (AAV) has emerged as the “gold standard” vehicle for gene therapy because it is non-pathogenic (it doesn’t cause disease in humans) and can effectively deliver genetic material into non-dividing cells like neurons.
In the case of Sangrail Biologics and similar clinical leaders, AAV is used as a microscopic “delivery truck.” The viral DNA is removed and replaced with a functional copy of the NAGLU gene. Once administered, the AAV vector travels to the patient’s cells and unloads the gene, allowing the cells to begin producing the missing enzyme themselves.
Successful and Safe Administration
Clinical trials for MPS IIIB have successfully utilized two primary routes of administration to bypass the protective blood-brain barrier:
- Intravenous (IV) Infusion: Using specific AAV serotypes (like AAV9) that have a natural ability to cross from the bloodstream into the brain. This is minimally invasive and provides systemic treatment for both the brain and peripheral organs like the liver.
- Intrathecal: Delivering the therapy directly into the brain tissue or the cerebrospinal fluid (CSF). Recent Phase 1/2 data has shown that these treatments are generally well-tolerated. Patients have demonstrated significant reductions in toxic heparan sulfate levels in their spinal fluid and, in many cases, a stabilization of cognitive decline—marking the first time in history that we have a tool capable of addressing the root cause of this "Holy Grail" of genetic diseases.
Proven Leadership in Advanced Therapies
Sangrail Biologics is led by an experienced team with deep expertise in gene therapy, clinical operations, manufacturing, and biotech growth. Our leadership drives innovation and advances new treatments for rare diseases.
Proven Leadership in Advanced Therapies
Sangrail Biologics is led by an experienced team with deep expertise in gene therapy, clinical operations, manufacturing, and biotech growth. Our leadership drives innovation and advances new treatments for rare diseases.
Coming Soon!
See You at ASGCT Oral Presentation #220 at 3:30PM EST on Wednesday, May 13
Systemic delivery of rAAV9.CMV.hNAGLU for mucopolysaccharidosis type IIIB is well-tolerated and shows biomarker evidence for early and sustained efficacy in a phase I/II trial.
In the News
The Latest from Sangrail Biologics
In the News
The Latest from Sangrail Biologics
April 20, 2026
News Post Title Lorem Ipsum Dolor Amet Elitis Sit, Consec Tetur Magna Quis Nostrud Ullamco Laboris Nisi Aliquip
By Sangrail Biologics
April 12, 2026
News Post Title Lorem Ipsum Dolor Amet Elitis Sit, Consec Tetur Magna Quis Nostrud Ullamco Laboris Nisi Aliquip
By Sangrail Biologics
Connect With Our Community Engagement Team
Connect with our team to learn more about available gene therapy options.
Connect With Our Investor Relations Team
Reach out to explore partnership opportunities and learn how Sangrail Biologics is advancing gene therapies.